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Human cytomegalovirus (HCMV) establishes a latent infection in hematopoietic cells, from which it can
reactivate to cause significant disease in immunocompromised individuals. HCMV expresses a functional
homolog of the immunosuppressive cytokine interleukin-10 (termed cmvIL-10), and alternate splicing of the
cmvIL-10 transcript results in expression of a latency-associated cmvIL-10 transcript (LAcmvIL-10). To
determine whether LAcmvIL-10 encodes immunosuppressive functions, recombinant LAcmvIL-10 protein was
generated, and its impact on major histocompatibility complex class II (MHC-II) expression was examined on
granulocyte macrophage progenitor cells (GM-Ps) and monocytes. LAcmvIL-10 (and cmvIL-10) downregulated
MHC-II on the surfaces of both cell types. This downregulation was associated with a decrease in total MHC-II
protein and transcription of components of the MHC-II biosynthesis pathway. Unlike cmvIL-10, LAcmvIL-10
did not trigger phosphorylation of Stat3, and its ability to downregulate MHC-II was not blocked by neutralizing antibodies to the human IL-10 receptor, suggesting that LAcmvIL-10 either does not engage the cellular
IL-10 receptor or utilizes it in a different manner from cmvIL-10. The impact of LAcmvIL-10 on dendritic cell
(DC) maturation was also assessed. In contrast to cmvIL-10, LAcmvIL-10 did not inhibit the expression of
costimulatory molecules CD40, CD80, and CD86 and the maturation marker CD83 on DCs, nor did it inhibit
proinflammatory cytokines (IL-1␣, IL-1␤, IL-6 and tumor necrosis factor alpha). Thus, LAcmvIL-10 retains
some, but not all, of the immunosuppressive functions of cmvIL-10. As GM-Ps and monocytes support latent
infection, expression of LAcmvIL-10 may enable HCMV to avoid immune recognition and clearance during
latency.

the degree of impairment of T-cell responses (41). Both major
histocompatibility complex class I (MHC-I)- and MHC-II-restricted HCMV-specific cytotoxic T lymphocyte responses are
generated and are important for virus clearance (31, 49).
MHC-II-restricted CD4⫹ cells act as critical antiviral effectors
as well as providing helper functions for maintaining HCMVspecific CD8⫹ T-cell responses (26), and impairment of the
HCMV-specific CD4⫹ T-cell response has been associated
with prolonged secretion of virus in young children (61). In a
study of CD4⫹ T-cell responses following primary HCMV infection in renal transplant recipients, van Leeuwen et al. (63)
provided evidence for the emergence of HCMV-specific CD4⫹
T cells that were represented during the latent phase of infection and that had the capacity to lyse HCMV antigen-expressing cells in an MHC-II-dependent manner (63). Thus, MHCII-restricted CD4⫹ T cells likely play an important role in the
control of productive infection and latency/reactivation. These
findings have led to the hypothesis that HCMV-encoded modulation of MHC-II would enhance the capacity of the virus to
limit the host immune response during both productive and
latent phases of infection. During latency, interference with
MHC-II expression leading to impairment of CD4⫹ T-cell
surveillance of latently infected cells may enhance the chances
for long-term maintenance of the virus. In this respect, experimental latent infection of cultured granulocyte macrophage
progenitor (GM-P) cells has been reported to result in a decrease in the expression of cell surface MHC-II molecules (52).

Human cytomegalovirus (HCMV) is a widely distributed
human herpesvirus with a highly restricted host range. It is the
prototypic betaherpesvirus with a life cycle that includes the
ability to establish a life-long latent infection within the host.
During latency, viral gene expression is highly restricted, and
infectious virions are not produced (36). Periodically, HCMV
is able to reactivate from latency, resulting in the production of
new infectious virus, a process which often leads to life-threatening disease in immunosuppressed individuals. While HCMV
infection causes mild or clinically nonapparent disease in the
immunocompetent host, it is a major cause of morbidity and
mortality in immunocompromised individuals such as patients
with AIDS, allograft recipients (bone marrow and solid organ),
and neonates (41). Despite the major clinical impact of this
virus on select populations, many aspects of HCMV biology
and pathogenesis remain poorly understood. In particular, little is known about the molecular mechanisms that underlie the
ability of the virus to persist in a latent form.
The cell-mediated immune response plays an important role
in the control of HCMV infection. In particular, clinical observations indicate that the severity of HCMV disease parallels
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Human interleukin-10 (hIL-10) is a pleiotropic cytokine that
exhibits potent immunomodulatory properties in hematopoietic cells (37). It has also been shown to be a critical determining factor in directing the induction of immunosuppression
leading to persistent (i.e., long-term productive) lymphocytic
choriomeningitis virus infection in vivo (7). During HCMV
productive and latent infections, the virus expresses transcripts
from the UL111A region which encode two homologs of hIL10. In productively infected cells, this homolog has been denoted cmvIL-10 (29, 32). Although the 175-amino-acid cmvIL-10
protein exhibits only 27% identity with hIL-10, this viral cytokine is still able to bind to and signal through the IL-10 receptor (IL-10R) (22, 54). Indeed, cmvIL-10 has been shown to
encode a broad range of immunosuppressive functions on myeloid cells comparable to those encoded by hIL-10. cmvIL-10
has been reported to inhibit peripheral blood mononuclear cell
(PBMC) proliferation and proinflammatory cytokine synthesis
(gamma interferon) and decrease surface expression of MHC-I
and MHC-II molecules on monocytes (54). It has also been
shown to induce functional paralysis of dendritic cells (DCs),
impairing lipopolysaccharide (LPS)-induced upregulation of
DC costimulatory molecules and altering cytokine production
(9, 46). In addition, Yamamoto-Tabata et al. (66) demonstrated that cmvIL-10 decreased matrix metalloproteinase activity and altered cell-cell and cell-matrix interactions of
HCMV-infected cytotrophoblasts and endothelial cells at the
uterine-placental interface (66). The authors suggest that this
may result in impaired cytotrophoblast remodeling of the uterine vasculature and consequently limit fetal growth.
During latent infection, altered splicing of the UL111A region transcript results in the expression of latency-associated
cmvIL-10 (LAcmvIL-10) (19). A similar transcript, which appears to initiate from a slightly different site, but which is
predicted to also encode LAcmvIL-10, has also been detected
during productive infection of human foreskin fibroblasts
(HFFs) (20). Thus, the LAcmvIL-10 open reading frame
(ORF) appears to be latency associated rather than latency
specific. Although colinear with cmvIL-10 at the amino terminus, LAcmvIL-10 is predicted to be a 139-amino-acid protein
with a truncated C terminus due to retention of the second
intron and the presence of an in-frame stop codon (19). The
detection of LAcmvIL-10 transcription during latent infection
raises the possibility that this variant of cmvIL-10 may encode
similar immunosuppressive properties. Thus, we sought to answer a number of questions addressing the capacity of LAcmvIL10 to exploit the immunosuppressive properties of hIL-10 as a
potential viral mechanism for evading the host’s immune system during the latent phase of infection. First, we applied a
combination of flow cytometry, immunofluorescence and confocal microscopy, Western blotting, and real time reverse transcription-PCR (RT-PCR) to examine the effects of recombinant LAcmvIL-10 on the expression of MHC-II molecules by
myeloid cell types shown to be important targets for HCMV
latency. Second, we examined the impact of LAcmvIL-10 on
Stat3 phosphorylation and its capacity to downregulate
MHC-II in the presence of neutralizing antibodies to hIL-10R
to gain insights into the mechanism of action of this viral
cytokine. Finally, we sought to determine whether LAcmvIL-10
retained any of the inhibitory characteristics displayed by
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cmvIL-10 within the context of DC maturation by assessing the
effect of this viral cytokine on the induction of DC maturation.

MATERIALS AND METHODS
Cells. HFFs and human embryonic kidney cells (HEK293) were grown in
Dulbecco’s modified Eagle’s medium (Gibco, Carlsbad, CA) supplemented with
10% heat-inactivated fetal calf serum (FCS) (CSL, Parkville, Australia). 9.22.3 is
a human B lymphoblastoid cell line with an HLA-DR␣ gene deletion (45) and
was kindly provided by E. D. Mellins (Stanford University). Cells were grown in
RPMI 1640 medium (GIBCO) supplemented with 10% heat-inactivated FCS.
Human fetal liver-derived hematopoietic cells were isolated and cultured as
GM-Ps, as previously described (27). On day 3 of culture, nonadherent cells were
collected, exposed to the various purified protein preparations, and incubated at
37°C in a humidified atmosphere containing 5% CO2.
PBMCs were isolated from healthy adult donors by density gradient sedimentation using Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala, Sweden)
and CD14⫹ monocytes isolated using anti-CD14 magnetic beads, according to
manufacturer’s instructions (Miltenyi Biotech, Auburn, CA). Isolated cells were
typically ⬎95% CD14⫹ as determined by flow cytometry analysis following staining with anti-CD14 antibody (clone MP9; fluorescein isothiocyanate [FITC]
conjugated; BD Biosciences, San Jose, CA).
Generation of monocyte-derived dendritic cells (MDDCs). CD14⫹ monocytes
were resuspended at 5 ⫻ 105 cells/ml in RPMI medium supplemented with 10%
heat-inactivated FCS, 500 U/ml IL-4, and 400 U/ml granulocyte-macrophage
colony-stimulating factor (GM-CSF) (Schering Plough, Kenilworth, NJ) and
allowed to adhere to 24-well tissue culture plates. Immature DCs were generated
as previously described (1, 8). Typically ⬎90% of cells were shown by flow
cytometry analysis to be of an immature DC phenotype (i.e., CD1a⫹ MHC-I⫹
MHC-II⫹ CD80low CD83⫺ CD86low). Mature DCs were generated by transferring the nonadherent immature DCs to new plates and culturing for a further 2
days in RPMI-GM medium containing 2 g/ml LPS (Sigma, St. Louis, MO), 400
U/ml GM-CSF, and 500 U/ml IL-4 for 2 days at 37°C in a 5% CO2 atmosphere
(2). These cultures consisted of ⬎90% mature DCs as determined by their
characteristic stellate shape and their cell-surface phenotype (i.e., CD1a⫹ MHCIhigh MHC-IIhigh CD80high CD83⫹ CD86high).
Antibodies. Flow cytometry was performed with allophycocyanin (APC)-conjugated mouse anti-human MHC-II (HLA-DR) monoclonal antibody (clone
L243) and FITC-conjugated mouse anti-human CD14 monoclonal antibody
(clone MP9) (BD Biosciences). Isotype antibodies used in parallel were APCconjugated mouse anti-human immunoglobulin G2a (IgG2a) and FITC-conjugated mouse anti-human IgG clone (X39; BD Biosciences). Monoclonal antibodies specific for human MHC-I (clone Tu149; phycoerythrin [PE] conjugated)
were from Caltag Laboratories (San Francisco, CA). PE-conjugated goat antimouse IgG, FITC-conjugated goat anti-human IgG, mouse IgG2a, PE-conjugated mouse IgG2a, and tricolor-conjugated mouse IgG2a antibodies were obtained from Caltag Laboratories (San Francisco, CA). PE-conjugated
monoclonal antibodies specific to human CD83 (clone HB15a) and human CD80
(clone MAB104) and unconjugated CD83 (clone HB15a) were obtained from
Immunotech (Marseilles, France). PE-conjugated anti-human CD86 (clone
IT2.2) and APC-conjugated anti-human CD1a (clone HI149) were obtained
from Pharmingen (Hamburg, Germany), and unconjugated anti-human
HLA-DR (clone IQU9) was obtained from Novocastra (Wetzlar, Germany).
Antibodies for immunofluorescence and confocal microscopy for the detection
of MHC-II were mouse anti-human MHC-II (HLA-DR) monoclonal antibody
(clone L243; Santa Cruz Biotechnology) and AlexaFluor 633-conjugated goat
anti-mouse antibody (Molecular Probes, Eugene, OR). Western blotting for
LAcmvIL-10 and cmvIL-10 was performed with goat anti-cmvIL-10 IgG polyclonal antibody (R&D Systems, Minneapolis, MN) and horseradish peroxidase
(HRP)-conjugated rabbit anti-goat IgG polyclonal antibody (Dako, Glostrup,
Denmark). For the detection of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), rabbit polyclonal IgG specific for GAPDH (clone FL335) and HRPconjugated goat anti-rabbit IgG polyclonal antibody were utilized (Santa Cruz
Biotechnology, CA). Western blot detection of Stat3 was carried out using
antibodies against total Stat (polyclonal rabbit anti-mouse Stat3; catalog no.
9132) or phospho-Stat3Y705 (polyclonal rabbit anti-mouse; catalog no. 9131)
(Cell Signaling Technology Inc., Danvers, MA). MHC-II detection was performed with monoclonal antibody specific for human MHC-II (HLA-DR␣; clone
DA6.147), kindly provided by E. D. Mellins (Stanford University), and HRPconjugated rabbit anti-mouse IgG polyclonal antibody (Dako, Glostrup, Denmark). Neutralizing antibodies to hIL-10R␣ and hIL-10R␤ were obtained from
R&D Systems (Minneapolis, MN).
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Construction of a LAcmvIL-10 bacterial cell expression vector and purification of recombinant LAcmvIL-10 protein. The LAcmvIL-10 amino acid sequence
includes a signal peptide with a cleavage site between residues 25 and 26 (P and
A, respectively). In order to generate a processed, i.e., cleaved, LAcmvIL-10
protein in a bacterial system, PCR primers were designed so that only the coding
nucleotide sequence subsequent to the signal peptide was cloned into a bacterial
cell expression vector (pET28a; Novagen). This vector tagged the amino terminus of the cloned protein with a His6 tag. The cDNA sequence of LAcmvIL-10
expressed in GM-Ps latently infected with HCMV strain Toledo was PCR amplified using primers SigSecA (5⬘-TTCCGAGGAGGAGGGATCCGCGACGA
CGACG-3⬘) and LAHinA (5⬘-GCTATGCCAAGCTTGTTACCTCTGTGCGG
A-3⬘), which were designed to introduce BamHI and HindIII restriction
endonuclease sites into the amplified product. The resultant PCR products were
then cloned into the pET28a vector using BamHI and HindIII. This construction
inserted the HCMV LAcmvIL-10 cDNA sequence, beginning 77 nucleotides
downstream of the translation start site and extending to the translational stop
codon of LAcmvIL-10.
Plasmid DNA encoding His-tagged LAcmvIL-10 was transformed into
competent E. coli BL21(DE3) cells, and protein expression was induced with
0.5 mM isopropyl-␤-D-thiogalactopyranoside. Final purification of recombinant LAcmvIL-10 was achieved by sequential ion exchange chromatography
using a ProBond Resin column (Invitrogen). The concentration of recombinant LAcmvIL-10 collected from sequential fractions was determined by
spectrophotometry.
Western blotting. Cells (5 ⫻ 105 cells/ml) to be analyzed for protein expression
were washed once in 1⫻ phosphate-buffered saline (PBS), lysed with cell lysis
buffer (150 mM NaCl, 20 mM HEPES, 1% Triton X-100, 1 mM Na3VO4, 1 mM
EDTA, and protease inhibitor cocktail I; Calbiochem), and incubated on ice for
30 min with agitation every 5 min. Lysed cells were then collected and centrifuged at 20,800 ⫻ g for 10 min at 4°C. The cell supernatants were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by electrotransfer to a positively charged nylon membrane (polyvinylidene
difluoride; Amersham Pharmacia Biotech, Uppsala, Sweden). Membranes were
incubated in blocking solution (5% nonfat milk in PBS) for 1 h and then
incubated with the relevant primary antibody diluted in blocking solution at
room temperature for 16 h. Unbound antibody was removed by several washes
in Tris-buffered saline–Triton X-100 (TBS-T; two washes for 30 s each and three
for 5 min each); the blot was then rinsed in 1⫻ TBS-T. The appropriate HRPconjugated secondary antibody was added, and the membrane was incubated at
room temperature for 30 min. Following antibody incubations, unbound antibody was removed by washing the membrane with TBS-T (two washes for 30 s
each and three for 5 min each). Bound secondary antibody was detected with an
ECL Plus Kit (Amersham Pharmacia Biotech), and exposed film was developed
using a CP1000 automatic developer (AGFA, Australia). The molecular weights
of proteins were determined using protein reference standards which were
loaded onto each gel (Bio-Rad, CA).
Immunostaining and flow cytometry analyses. Cells to be analyzed for expression of cell surface molecules by flow cytometry were first harvested, washed in
1⫻ PBS, pelleted by centrifugation, and washed in fluorescence-activated cell
sorting (FACS) buffer (PBS with 1% FCS–0.2% sodium azide). Cells resuspended in 100 l of FACS buffer were incubated with the relevant primary
antibody at 4°C in the dark for 20 min. Following incubation, the cells were
washed in FACS buffer and then centrifuged. If an unconjugated primary antibody was used, a second incubation with the appropriate fluorochrome-conjugated secondary antibody was performed in the same manner. Following a final
wash in FACS buffer, the cell pellets were then resuspended in 150 l of FACS
buffer for immediate analysis or fixed in 150 l of 1% (vol/vol) paraformaldehyde
for analysis at a later time point using a FACSCalibur instrument and CellQuest
software (BD Biosciences). Positive and negative staining with cell-surface-specific antibodies was determined by the level of fluorescence that exceeded, or did
not exceed, levels obtained by 98% of the cells from the same starting population
when incubated with isotype control primary antibodies.
Immunofluorescence staining and confocal microscopy. Cells (5 ⫻ 104) were
cytospun onto glass slides, air dried, fixed in 4% paraformaldehyde in PBS for 10
min, and permeabilized with 0.2% Triton X-100 in PBS for 15 min at room
temperature. Slides were washed three times in PBS and incubated with blocking
buffer (10% normal donkey serum in PBS) for 1 h at 37°C in a humidified
atmosphere before staining. Slides were washed with PBS and incubated with
primary goat anti-human CD14 (1:100 dilution), mouse anti-human HLA-DR
(1:25 dilution), or the appropriate isotype control antibodies for 1 h. Cells were
then either incubated with AlexaFluor 488 rabbit anti-goat IgG conjugate (1:200
dilution) for 30 min or AlexaFluor 633 goat anti-mouse IgG conjugate (1:50
dilution) for 1 h. All antibodies were diluted in blocking buffer and incubated at
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37°C in a humidified atmosphere in the dark. Following each antibody incubation, slides were washed three times in PBS. Slides were mounted in SlowFade
Gold antifade mounting medium (Molecular Probes), and cells were examined
using a Leica laser scanning confocal microscope.
RNA extraction and real-time quantitative RT-PCR. Total RNA was isolated
from monocytes using an RNAqueous kit (Ambion, Texas) according to the
manufacturer’s instructions. cDNA was synthesized from total RNA using random hexamers and Superscript III reverse transcriptase (Invitrogen, CA). The
cDNA product was used for real-time quantitative PCR using a high-speed
thermal cycler (Stratagene Mx3005P; Applied Biosystems, CA), and the quantitative PCR products were detected by using Sybr green PCR SuperMix (Invitrogen, CA) according to the manufacturer’s instructions. The PCR cycling
conditions were as follows: 1 cycle of 2 min at 50°C and 2 min at 95°C; 50 cycles
of 15 s at 95°C and 45 s at 45°C; and then 1 cycle of 1 min at 95°C, 30 s at 55°C,
and 30 s at 95°C. Three housekeeping genes, GAPDH, beta actin, and lactate
dehydrogenase (LDHA), were included to assess the relative changes in gene
expression between different treatments. The amplification efficiencies for each
primer pair were determined by creating standard curves with 10-fold serial
dilution of pooled cDNA. The log of the relative target quantity was plotted
versus the cycle threshold values. Specific cDNA was quantified using this standard curve. All results are normalized with respect to the three housekeeping
genes and expressed relative to the expression level of the mock treatment.
Primer sequences were as follows: MHC-II alpha chain, 5⬘-CCACCAGTGGTC
AATGTCAC-3⬘ (forward) and 5⬘-CCTGCAGTCGTAAACGTCCT-3⬘ (reverse); MHC-II beta chain, 5⬘-AGGCAGCATTGAAGTCAGGT-3⬘ (forward)
and 5⬘-GGCAGGTGTAAACCTCTCCA-3⬘ (reverse); invariant chain, 5⬘-CTC
CAGTGCTATGGGAGCAT-3⬘ (forward) and 5⬘-AGATCCTGCTTGGTCAC
ACC-3⬘ (reverse); class II transactivator (CIITA), 5⬘-AGGTCTCCAACAAGC
TTCCA-3⬘ (forward) and 5⬘-CTCTTGCTGCTGCTCCTCTC-3⬘ (reverse);
GAPDH, 5⬘-GAGTCAACGGATTTGGTCGT-3⬘ (forward) and 5⬘-GACAAG
CTTCCCGTTCTCAG-3⬘ (reverse); beta actin, 5⬘-AGAAAATCTGGCACCAC
ACC-3⬘ (forward) and 5⬘-GGGGTGTTGAAGGTCTCAAA-3⬘ (reverse); and
LDHA, 5⬘-TGGGAGTTCACCCATTAAGC-3⬘ (forward) and 5⬘-AGCACTCT
CAACCACCTGCT-3⬘ (reverse).
Multiplex enzyme-linked immunosorbent assay (ELISA). The levels of multiple proinflammatory cytokines in clarified supernatants derived from DC cultures were measured using Fluorokine MAP (multianalyte profiling; R & D
Systems) technology following the manufacturer’s directions. Briefly, cytokinespecific antibodies (i.e., IL-1␣, IL-1␤, IL-6, tumor necrosis factor alpha [TNF-␣],
and GM-CSF) were precoated onto color-coated microparticles and were added
to clarified DC culture supernatant samples to be assayed in a 96-well filterbottomed microplate (R&D Systems). The mixture was incubated at room temperature for 3 h with gentle shaking to allow the cytokines of interest to bind to
the immobilized antibodies. Bound analytes were washed three times, and biotinylated antibodies specific to the analytes of interest were added to each well
and incubated for 1 h longer at room temperature with gentle shaking. Unbound
biotinylated antibodies were removed by washing, and a streptavidin-PE conjugate was added to each well to bind to the biotinylated detection microparticles.
Following washes to remove unbound streptavidin-PE-conjugated antibody, the
samples were then read using a Bio-Plex analyzer, a dual laser, and a flow
cytometry-based sorting and detection platform manufactured by Bio-Rad (Hercules, CA).

RESULTS
Impact of LAcmvIL-10 on cell surface MHC-II expression
by myeloid cells. Latent HCMV infection has been shown to
downregulate cell surface MHC-II expression on cultured
CD14⫹ primary human GM-Ps (52). As a consequence of the
detection of LAcmvIL-10 transcripts in latently infected
GM-Ps (19), we sought to determine whether LAcmvIL-10
protein could function to alter the constitutive expression of
cell surface MHC-II on primary human GM-Ps using recombinant proteins generated using bacterial and mammalian cell
expression systems.
LAcmvIL-10 protein was generated from E. coli cells transformed with a His-tagged LAcmvIL-10 expression vector. Recombinant LAcmvIL-10 or mock protein from parental vectortransformed cells was subjected to purification by sequential
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FIG. 1. MHC-II and CD14 expression on the surface of GM-Ps following treatment with purified LAcmvIL-10 and cmvIL-10. (A) Western blot
of purified cmvIL-10 and purified LAcmvIL-10 separated by SDS-PAGE. Both proteins reacted with the polyclonal anti-cmvIL-10 antibody used
to probe the blot with cmvIL-10 detected at 17.6 kDa and His-tagged LAcmvIL-10 detected at the predicted size of 16.8 kDa. Sizes of
corresponding molecular mass markers are indicated in kilodaltons (kDa). (B) Histogram plot showing a decrease in surface MHC-II by
LAcmvIL-10 and cmvIL-10 relative to mock protein preparation. Panels C to F show flow cytometric analyses of the expression of MHC-II (C and
E) and CD14 (D and F) molecules on the surface of CD14⫹ GM-Ps treated with either bacterial cell-expressed and purified LAcmvIL-10 and
cmvIL-10 (C and D) or conditioned medium (CM) from mammalian cells transfected with LAcmvIL-10 and cmvIL-10 expression vectors (E
and F). The relative MFIs of surface MHC-II and CD14 molecules are shown with the means and standard errors calculated from four replicate
experiments. Each data point represented the relative MFI of a given surface molecule (relative MFIM) on the various treatments of GM-Ps,
calculated as follows: (MFIM on GM-Ps(treated)/MFIM on GM-Ps(mock)) ⫻ 100, where GM-Ps are treated with cmvIL-10, LAcmvIL-10, or mock
preparation. Significant differences from the mock-treated control were determined using a one-tailed, paired Student’s t test and are indicated
as follows: *, P ⬍ 0.05; **, P ⬍ 0.005; ***, P ⬍ 0.0005.

ion-exchange chromatography and analysis by SDS-PAGE and
Western blotting using an anti-cmvIL-10 antibody (Fig. 1A).
Recombinant epitope-tagged LAcmvIL-10 protein was readily
detected at the predicted size of 16.8 kDa, as was the positive
control, bacterial cell-expressed cmvIL-10 at 17.6 kDa (R&D
Systems). Antibody did not react with the mock protein sam-

ple. It was concluded that recombinant LAcmvIL-10 was successfully expressed by and purified from E. coli. For production
of mammalian cell-expressed proteins, LAcmvIL-10 and
cmvIL-10 cDNAs were cloned, and recombinant proteins
were expressed in HEK293 cells as previously described
(20). A mock control consisting of HEK293 cells transfected
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with the empty parental vector was also generated. This
approach resulted in the successful expression and secretion
of LAcmvIL-10 and cmvIL-10 proteins from transfected
HEK293 cells (20).
MHC-II expression was first assessed on GM-Ps treated with
bacterial cell-expressed, purified LAcmvIL-10 or cmvIL-10
proteins. GM-Ps isolated from fetal liver were grown in suspension culture in GM-P medium (27) for 7 days prior to
treatment with either cmvIL-10 (25 ng/ml), LAcmvIL-10 (100
ng/ml), or a preparation derived from the purification of bacterial cells transformed with a parental vector, which constituted the mock treatment. Forty-eight hours posttreatment,
GM-Ps were stained for CD14 and MHC-II and analyzed by
flow cytometry (Fig. 1B to D). In four independent replicate
experiments treatment of GM-Ps with either LAcmvIL-10 or
cmvIL-10 resulted in a statistically significant decrease in the
expression of cell surface MHC-II on CD14⫹ GM-Ps (Fig. 1C).
Treatment of GM-Ps with cmvIL-10 also resulted in modest
enhancement of CD14 expression on the surface of cells
(Fig. 1D).
In addition to assessment of GM-Ps treated with bacterial
cell-expressed proteins, GM-Ps cultured for 7 days were also
treated with 50% volumes of conditioned GM-P medium from
either LAcmvIL-10-, cmvIL-10-, or parental vector-transfected
HEK293 cells and cultured for a further 2 days. GM-Ps were
then immunostained for the monocyte lineage cell marker
CD14 and for MHC-II (HLA-DR) expression and were analyzed by flow cytometry. The mean fluorescence intensity
(MFI) of cell surface MHC-II expression was determined from
gated CD14⫹ GM-Ps. Although the amount of cmvIL-10 and
LAcmvIL-10 protein secreted into the culture medium by
transfected cells could not be accurately quantitated or standardized, in comparison with GM-Ps treated with conditioned
medium from parental vector-transfected cells, treatment with
either LAcmvIL-10- or cmvIL-10-conditioned medium resulted in reduced levels of MHC-II staining (Fig. 1E). Treatment of GM-Ps with cmvIL-10 also resulted in modest enhancement of cell surface CD14 expression compared to
parental vector-treated GM-Ps (Fig. 1F). In four independent
replicate experiments using four separate GM-P cultures (i.e.,
different donors), treatment with either cmvIL-10- or LAcmvIL10-conditioned medium resulted in a statistically significant
(P ⬍ 0.05) reduction in the expression of MHC-II on the
surfaces of CD14⫹ GM-Ps. These results demonstrate that
both the LAcmvIL-10 and cmvIL-10 derived from either mammalian cells or purified from a bacterial expression system
exhibited the ability to downregulate MHC-II expression on
CD14⫹ GM-Ps, a cell type shown to support latent HCMV
infection.
To determine whether LAcmvIL-10 downregulated MHC-II
in a dose-dependent manner, GM-Ps were treated for 48 h with
10-fold decreasing concentrations of purified LAcmvIL-10 protein (100 ng/ml to 1 pg/ml) before being stained for CD14 and
MHC-II and then analyzed by flow cytometry (Fig. 2A).
GM-Ps were similarly treated with cmvIL-10 and mock protein
preparations. Treatment with decreasing concentrations of either LAcmvIL-10 or cmvIL-10 resulted in a loss of the ability
of these proteins to downregulate MHC-II on the surfaces of
CD14⫹ GM-Ps. There was little difference between these
IL-10 homologs in their capacities to downregulate MHC-II,
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and this capacity was lost at the same dosage. This dosedependent effect was observed in no fewer than three replicate
experiments and was statistically significant. In addition to
more primitive hematopoietic cells such as GM-Ps, PBMCs
have also been shown to be an important reservoir of latent
HCMV (53, 58–60). Thus, the impact of LAcmvIL-10 on these
cells was also assessed. CD14⫹ monocytes isolated from fresh
peripheral blood were treated with decreasing concentrations
of LAcmvIL-10, cmvIL-10, or mock protein preparations. As
in GM-Ps, LAcmvIL-10 and cmvIL-10 downregulated surface
MHC-II by CD14⫹ monocytes in a dose-dependent manner
(Fig. 2B). Thus, LAcmvIL-10 and cmvIL-10 possessed an ability to interfere with the expression of surface MHC-II molecules on both immature myeloid progenitor cells (i.e., GM-Ps)
and primary human monocytes. Although previous studies
demonstrating biological function of cmvIL-10 were performed with recombinant protein containing a histidine (His)
epitope tag (54), our current work utilized a commercially
available, tag-free cmvIL-10. As the LAcmvIL-10 protein we
generated still contained the epitope tag, we generated our
own His-tagged cmvIL-10 and compared it with commercially acquired cmvIL-10 for capacity to downregulate
MHC-II on monocytes. This analysis confirmed that the His
tag did not alter the immunosuppressive properties of virally
encoded IL-10s (data not shown).
Total cellular MHC-II protein synthesis and localization in
monocytes treated with LAcmvIL-10 and cmvIL-10. Successful
expression of MHC-II at the cell surface is the result of a
multistep biosynthesis and assembly pathway (12, 44). To examine levels of total cellular MHC-II protein, we performed
Western blotting of CD14⫹ monocytes treated either with
mock or with LAcmvIL-10- or cmvIL-10-purified protein preparations. Forty-eight hours after treatment, lysates of 2 ⫻ 105
CD14⫹ monocytes were prepared, and proteins were separated by SDS-PAGE. Lysates of the B cell line 9.22.3, which
has a deletion in the HLA-DR␣ gene and consequently does
not express MHC-II (HLA-DR), was included as a negative
control (44). Immunoblot analysis was carried out with the
anti-MHC-II (HLA-DR␣) antibody DA6.147 in conjunction
with the ECL detection system (Amersham Pharmacia Biotech). A 33-kDa fragment corresponding to the MHC-II HLADR␣ chain was detected in mock-, LAcmvIL-10-, and cmvIL10-treated samples, but the amount of MHC-II expressed by
cells treated with LAcmvIL-10 and cmvIL-10 was less than that
of the mock-treated sample (Fig. 3A). Comparable protein
loading of samples was confirmed by reprobing the membrane
for the housekeeping gene GAPDH. Densitometer analysis of
MHC-II bands was performed, and the data were normalized
to GAPDH expression from three replicate experiments. This
analysis demonstrated that, compared to mock-treated cells,
LAcmvIL-10 and cmvIL-10 significantly decreased total cellular MHC-II expression (Fig. 3B).
To determine whether LAcmvIL-10 or cmvIL-10 altered
MHC-II protein localization, immunofluorescence staining
was performed. Human CD14⫹ monocytes were incubated
with either 100 ng/ml purified LAcmvIL-10 or cmvIL-10 protein or with mock protein preparations and analyzed for
MHC-II (HLA-DR) expression at 48 h using monoclonal antibody (clone L243) and an AlexaFluor 633-conjugated goat
anti-mouse IgG as a secondary antibody (Fig. 4). The pattern
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FIG. 2. Ability of LAcmvIL-10 and cmvIL-10 to downregulate cell surface MHC-II on GM-Ps and monocytes in a dose-dependent manner.
GM-Ps (A) and monocytes (B) were treated for 48 h with 10-fold decreasing concentrations of purified LAcmvIL-10, cmvIL-10, and mock protein
preparations before being stained for CD14 and MHC-II and analyzed by flow cytometry. The relative MFIs of MHC-II surface molecules are
shown with the means and standard errors calculated from at least three separate experiments. Each data point represents the relative MFI of a
given surface molecule (relative MFIM) on the various treatments of GM-Ps, calculated as follows: (MFIM on GM-Ps(treated)/MFIM on GMPs(mock)) ⫻100, where GM-Ps are treated with cmvIL-10, LAcmvIL-10, or mock preparation. Significant differences from the mock-treated control
were determined using a one-tailed, paired Student’s t test and are indicated as follows: ⴱ, P ⬍ 0.05; ⴱⴱ, P ⬍ 0.005; ⴱⴱⴱ, P ⬍ 0.0005, ⴱⴱⴱⴱ, P ⬍
0.00005.

of MHC-II staining was then determined by counting a minimum of 300 cells from each treatment under a magnification of
⫻400. In nine independent replicate experiments, 73.1% ⫾
6.2% (⫾ standard error of the mean) of monocytes treated
with the mock protein preparation displayed a clear and strong
surface staining pattern of MHC-II. In contrast, only 15.7% ⫾
11.8% of monocytes treated with LAcmvIL-10 and 33.1% ⫾
9.4% of cmvIL-10-treated cells stained positive for cell-surface
MHC-II. In addition to reduced cell surface MHC-II staining,
a punctate vesicular pattern was observed in a very small proportion of cells treated with either LAcmvIL-10 (3.5% ⫾
1.5%) or cmvIL-10 (5.4% ⫾ 2.1%). This pattern of punctate
staining was not observed in any cells treated with the mock
protein preparation. No staining was detected in monocytes
incubated with isotype control antibody. These results indicate

that both LAcmvIL-10 and cmvIL-10 reduce total MHC-II
protein expression in monocytes and, in a very small proportion of cells, lead to the accumulation of MHC-II molecules
within cytoplasmic vesicles.
Impact of LAcmvIL-10 and cmvIL-10 on transcription of
components of the MHC-II biosynthesis pathway. MHC-II
molecules are heterodimers consisting of an ␣ and ␤ chain
which present peptides to CD4⫹ T lymphocytes. The ␣ and ␤
chains form a heterodimer in the endoplasmic reticulum and
associate with the invariant chain. Processing of the invariant
chain in cytosolic endosomes ultimately results in its removal,
enabling peptides to be loaded onto the ␣/␤ chain heterodimer, and this peptide-loaded MHC-II molecule is presented on the cell surface (12, 44, 65). To determine whether
LAcmvIL-10 and cmvIL-10 inhibited the transcription of com-
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FIG. 3. Expression of MHC-II protein by CD14⫹ monocytes treated with LAcmvIL-10 and cmvIL-10. (A) MHC-II (HLA-DR␣) Western
blotting performed on whole-cell lysates from monocytes treated with mock, cmvIL-10, or LA-cmvIL-10 protein preparations. Lysates from
HLA-DR⫺ 9.22.3 cells were included as a negative control. The immunoblot was reprobed for the housekeeping gene GAPDH (bottom panel).
(B) Graph depicting densitometer analysis of MHC-II bands from three replicate Western blotting experiments following normalization to
GAPDH expression. Significant differences from the mock-treated control were determined using a one-tailed, paired Student’s t test.*, P ⬍ 0.05.

ponents of the MHC-II pathway, RNA extracted from monocytes 48 h after incubation with mock, LAcmvIL-10, or
cmvIL-10 proteins was assessed by real-time RT-PCR using
primers specific for MHC-II (HLA-DR) ␣, ␤, and invariant
chains. The level of transcription of each MHC-II component
was determined following normalization to three housekeeping genes, GAPDH, ␤-actin, and LDHA. In a total of three
independent replicate experiments, by comparison with mock
protein-treated cells, both LAcmvIL-10 and cmvIL-10 significantly inhibited transcription of ␣, ␤, and invariant chains (Fig.
5A to C). A master regulatory factor, CIITA, regulates the
transcription of genes involved in the MHC-II biosynthesis
pathway, including ␣, ␤, and invariant chains (48). Real-time
RT-PCR was therefore also extended to assess CIITA RNA
levels. This analysis demonstrated that both LAcmvIL-10 and
cmvIL-10 significantly inhibited CIITA transcription (Fig. 5D).
These data are consistent with the idea that LAcmvIL-10 and
cmvIL-10 downregulate MHC-II by interfering with CIITA.
Ability of LAcmvIL-10 to signal through hIL-10R. cmvIL-10
has been shown previously to bind and signal through hIL-10R
(22, 29, 54). To examine the signaling events induced by
LAcmvIL-10, monocytes were treated with recombinant hIL-10,
cmvIL-10, or LAcmvIL-10 for 10 min. Cell lysates were then
analyzed for the activation of the transcription factor Stat3, a
well-documented signaling outcome following activation of IL10R (14). Western blotting of cell lysates revealed that Stat3
became phosphorylated on tyrosine 705 in response to treatment with both cmvIL-10 and hIL-10 (Fig. 6A). However, no
phosphorylation of Stat3 was detected in monocytes treated
with LAcmvIL-10. Polyclonal antiserum directed to the Stat3
protein was used to visualize the total amount of Stat3 in each
lysate and to confirm that each lane contained the same
amount of protein.
To investigate whether LAcmvIL-10 triggered Stat3 phosphorylation with delayed kinetics relative to hIL-10 or cmvIL-

10, monocytes were treated with 10 ng/ml cytokine and incubated at 37°C for 10, 30, or 60 min. Cell lysates were then
prepared and analyzed for Stat3 phosphorylation (Fig. 6B).
For cells treated with cmvIL-10, the most intense signal occurred in cells treated for 10 min, with the amount of phosphoStat3 decreasing slightly at the 30- and 60-min time points. In
contrast, LAcmvIL-10 treatment did not trigger phosphorylation of Stat3, even at the extended time points, suggesting
either that this protein does not engage the cellular IL-10R or
that it utilizes this receptor in a manner that differs from that
of hIL-10 and cmvIL-10. An alternative explanation for this
finding is that there may have been some inhibitor in the
LAcmvIL-10 preparation which prevented Stat3 activation. To
examine this possibility, cells were treated with both cmvIL-10
and LAcmvIL-10 in combination, and then Stat3 activation was
evaluated by Western blotting. As shown in Fig. 6C, Stat3
phosphorylation was observed in response to treatment with
cmvIL-10, whether alone or in combination with LAcmvIL-10.
These findings confirm that LAcmvIL-10 neither induces Stat3
phosphorylation nor blocks Stat3 activation by cmvIL-10.
To assess binding of LAcmvIL-10 to the hIL-10R, GM-Ps
were either left untreated or treated for 2 h with a combination
of neutralizing antibodies to hIL-10R␣ (25 g/ml) and hIL10R␤ (25 g/ml) before being incubated with mock-, cmvIL10-, or LAcmvIL-10-treated proteins and incubated for a further 48 h. Cells were immunostained with anti-CD14-FITC
and anti-HLA-DR-APC or with their isotype controls, mouse
IgG2a-FITC and mouse IgG2a-APC, respectively. HLA-DR
expression on CD14⫹ cells was assessed by flow cytometry for
each treatment (Fig. 7A), with the MFI of antibody staining for
HLA-DR and CD14 calculated relative to mock-treated cells.
The impact of hIL-10R neutralizing antibodies on the downmodulation of MHC-II (HLA-DR) following treatment with
LAcmvIL-10 and cmvIL-10 was assessed in a total of four
independent replicate experiments (Fig. 7B). Incubation with
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FIG. 4. Analysis of MHC-II (HLA-DR) protein localization in
LAcmvIL-10- and cmvIL-10-treated CD14⫹ monocytes. Immunofluorescence staining and confocal microscopy visualization of MHC-II
(HLA-DR; red staining) in monocytes treated with mock protein preparation (A), LAcmvIL-10 (C and E), and cmvIL-10 (G). Cells stained
with isotype control antibody are shown in panel I. Corresponding
phase-contrast images from each treatment are shown (B, D, F, H, and
J). Arrows indicate the appearance of punctate cytoplasmic MHC-II
staining in a small proportion of cells treated with LAcmvIL-10 and
cmvIL-10. White bars indicate size.

either cmvIL-10 or LAcmvIL-10 significantly reduced
HLA-DR expression on CD14⫹ GM-Ps that had not been
pretreated with hIL-10R neutralizing antibodies. When neutralizing antibodies were added, the downregulation of
HLA-DR by cmvIL-10 was almost completely inhibited. In
contrast, LAcmvIL-10 continued to downregulate HLA-DR in
the presence of IL-10R neutralizing antibodies. Thus, neutralizing antibodies to the hIL-10R inhibited the MHC-II modulating function of cmvIL-10 but did not affect the function of
LAcmvIL-10. It was concluded that LAcmvIL-10 functioned to
downregulate HLA-DR cell surface expression on CD14⫹
GM-Ps using a mechanism independent of cmvIL-10 and
possibly independent of hIL-10R.
Impact of LAcmvIL-10 on the maturation of DCs. In response to pathogens, DCs undergo maturation, which is characterized by profound phenotypic changes that enable subsequent T-lymphocyte activation. This includes the upregulation
of the costimulatory and adhesion molecules CD40, CD80,
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CD83, and CD86 as well as an increase in MHC expression and
the secretion of proinflammatory cytokines such as TNF-␣,
IL-6, and IL-1-␤ (3, 24, 43, 62). These phenotypic changes are
significantly impaired by immunosuppressive cytokines such as
hIL-10, which inhibits DC maturation (34). In MDDCs, Chang
et al. (9) and Raftery et al. (46) showed that cmvIL-10 mimics
the effects of hIL-10 by impairing upregulation of DC costimulatory and adhesion molecules and proinflammatory
cytokine production in response to the DC maturation stimulus LPS (9, 46).
To determine whether LAcmvIL-10 could function to inhibit
DC maturation, DCs generated from human CD14⫹ monocytes by culture with GM-CSF and IL-4 were induced to mature with LPS (1 g/ml) in the presence of increasing concentrations of purified LAcmvIL-10 (60 ng/ml, 120 ng/ml, or 750
ng/ml) or mock protein preparation. Purified cmvIL-10 (25
ng/ml) was included as a positive control for impairment of DC
maturation. Immature DCs incubated in the absence of LPS or
viral IL-10s were also included to establish baseline levels of
immune molecule expression prior to maturation.
Treatment of DC with LPS in the presence of cmvIL-10
resulted in impaired upregulation of the costimulatory molecules CD40, CD80, and CD86, the maturation marker CD83,
and also MHC-I (Fig. 8). In stark contrast, treatment of DCs
with LAcmvIL-10 did not result in any significant change in
molecule expression in comparison to the LPS-treated DCs
incubated with the mock protein preparation (i.e., mature DC
control). Analysis of data from four replicate experiments
demonstrated significant inhibition of upregulation of CD40,
CD80, CD83, CD86, and MHC-I in the presence of cmvIL-10
but not in the presence of LAcmvIL-10, despite concentrations
of LAcmvIL-10 as high as 750 ng/ml. Similarly, conditioned
medium from HEK293 cells transfected with the cmvIL-10
expression vector inhibited the upregulation of immune molecules on immature DCs induced to mature with LPS, whereas
conditioned medium from LAcmvIL-10-transfected cells did
not (data not shown). It was concluded that cmvIL-10, but not
LAcmvIL-10, functions to inhibit the upregulation of costimulatory and adhesion molecules by DCs in response to LPS
treatment.
Both hIL-10 and cmvIL-10 have previously been shown to
inhibit LPS-induced secretion of proinflammatory cytokines
such as TNF-␣, IL-6, and IL-1-␤ by DCs (9, 34, 46). Consequently, we also sought to determine whether LAcmvIL-10
altered cytokine secretion from DCs induced to mature with
LPS. Immature DCs were stimulated with LPS (1 g/ml) in the
presence of 50% volumes of conditioned medium from either
LAcmvIL-10-, cmvIL-10-, or parental vector-transfected
(mock) HEK293 cells and cultured for 3 days. Purified
cmvIL-10 (25 ng/ml) was used as a positive control for inhibition
of DC maturation, and immature DCs not stimulated with LPS
were used as a negative control. Supernatants from four replicate DC cultures were collected and clarified by low-speed
centrifugation, and the levels of IL-1␣, IL-1␤, IL-6, TNF-␣,
and GM-CSF were analyzed using a multiplex sandwich
ELISA (Fig. 9). Mock-treated DC induced with LPS showed a
marked induction of secretion of the proinflammatory mediators IL-1␣, IL-1␤, IL-6, and TNF-␣. In comparison, the addition of purified cmvIL-10 protein or cmvIL-10-conditioned
medium in the presence of LPS stimulation significantly inhib-
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FIG. 5. Analysis of mRNA expression of components of the MHC-II biosynthesis pathway. Quantitative real-time RT-PCR analysis of
HLA-DR␣ chain (A), HLA-DR␤ chain (B), invariant chain (C), and CIITA (D) mRNA expression in monocytes treated for 48 h with mock,
cmvIL-10, or LAcmvIL-10 protein preparations. Significant differences from the mock-treated control were determined using a one-tailed, paired
Student’s t test. **, P ⬍ 0.005.

ited IL-1␣, IL-1␤, IL-6, and TNF-␣ production. In contrast,
treatment of DCs with LPS in the presence of LAcmvIL-10conditioned medium showed no inhibition of any of these
cytokines in comparison with mock-treated cells. Production of
the cytokine GM-CSF was not altered significantly in the presence of either purified cmvIL-10 or conditioned medium from
cmvIL-10- or LAcmvIL-10-transfected cells compared to levels
detected in mock-treated DCs. Taken together with the cell
surface molecule analyses, these data demonstrate that cmvIL10, but not LAcmvIL-10, inhibits LPS-induced maturation of
MDDCs.
DISCUSSION

FIG. 6. Activation of Stat3 by cmvIL-10 but not LAcmvIL-10.
(A) Primary human CD14⫹ monocytes were left untreated (Control)
or treated with 10 ng/ml purified hIL-10, cmvIL-10, or LAcmvIL-10
protein preparations for 10 min. Cell lysates were then immunoblotted
with polyclonal antiserum to detect phosphorylated or total unmodified Stat3 protein as indicated. (B) Monocytes were treated with 10
ng/ml purified cmvIL-10 or LAcmvIL-10 for increasing times and then
immunoblotted as described above. (C) Monocytes were incubated
with 10 ng/ml for each indicated cytokine or combination of cytokines
for 10 min before lysis and blotting.

This study represents the first functional assessment of
HCMV LAcmvIL-10 protein, addressing the capacity of
LAcmvIL-10 to exploit the immunosuppressive properties
of hIL-10 as a viral mechanism for potentially limiting the effectiveness of the host’s immune system during the latent phase of
infection. Significantly, recombinant LAcmvIL-10 exhibited a
dose-dependent ability to downregulate constitutive levels of
MHC-II on the surfaces of both GM-Ps and monocytes, cell
types known to be important sites of HCMV latency. The
ability of LAcmvIL-10 to interfere with MHC-II expression
was comparable to that of the related protein cmvIL-10, a
functional homolog of hIL-10 which is expressed from the
UL111A region of the HCMV genome during productive infection (29, 32, 54).
Consistent with the flow cytometry analysis, immunofluorescence and confocal microscopy demonstrated a reduction in
the number of LAcmvIL-10- and cmvIL-10-treated monocytes
expressing surface MHC-II. In the vast majority of these cells,
the loss of cell surface staining corresponded with a general
loss of cellular MHC-II staining. However, in a very small
proportion of cells, the loss of cell surface staining was asso-
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FIG. 7. Capacity of LAcmvIL-10 and cmvIL-10 to downregulate MHC-II in the presence of neutralizing antibody to hIL-10R. Flow cytometric
analysis of MHC-II (HLA-DR) expression on CD14⫹ GM-Ps following incubation without (A) or with (B) anti-hIL-10R␣/␤ neutralizing
antibodies, prior to treatment with either LAcmvIL-10, cmvIL-10, or mock protein preparations. (C) The relative MFI values of surface MHC-II
are shown with the means and standard errors calculated from four independent replicate experiments. Each data point represents the relative MFI
of a given surface molecule (relative MFIM) on the various treatments of GM-Ps, calculated as follows: (MFIM on GM-Ps(treated)/MFIM on
GM-Ps(mock)) ⫻100, where GM-Ps are treated with the cmvIL-10, LAcmvIL-10, or mock preparation. Significant differences from mock treatments
were determined using a one-tailed, paired Student’s t test. *, P ⬍ 0.05.

ciated with the appearance of a punctate vesicular staining
pattern in the cytoplasm. We have previously reported a decrease in MHC-II expression on the surfaces of GM-Ps latently
infected with HCMV, concomitant with a retention of MHC-II
protein within HLA-DM⫹ cytoplasmic vesicles (52). Furthermore, Koppelman et al. (28) demonstrated that hIL-10 downregulates MHC-II expression at the plasma membrane of
monocytes by affecting the exocytosis and recycling of MHC-II
peptide complexes and by suppressing the reexpression of internalized MHC-II on the plasma membrane affecting the recycling pool of these molecules (28). MHC-II was shown to
localize to vesicles that costained with the endosomal markers
HLA-DM and CD63. It was suggested that hIL-10 affects the
biosynthetic pool of MHC-II, an idea which is based on the

observation that HLA-DM identifies lysosomal-like structures
through which the majority of newly synthesized MHC-II must
negotiate on the way to the plasma membrane (5, 64). It is
therefore tempting to speculate that LAcmvIL-10 may function to suppress the host’s ability to successfully mount an
immune response against the virus in its latent form by affecting MHC-II exocytosis and recycling in latently infected cells.
Although the observations reported previously in latently
HCMV-infected GM-Ps and in hIL-10-treated monocytes
share similarities with the observations of altered MHC-II localization by LAcmvIL-10 and cmvIL-10 in the current study,
a decrease in total MHC-II in these cells was not reported in
infected GM-Ps or hIL-10-treated monocytes. A more detailed
examination of the MHC-II biosynthesis pathway, together
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FIG. 8. Effect of LAcmvIL-10 and cmvIL-10 on MDDC maturation following LPS stimulation. Flow cytometric analysis of the expression of
CD40, CD80, CD83, CD86, and MHC-I molecules on the surface of LPS-induced DCs. The relative MFIs of surface molecules are shown with
the means and standard errors calculated from four separate experiments. Each data point represents the relative MFI of a given surface molecule
(relative MFIM) on the various treatments of LPS-induced DCs, calculated as follows: (MFIM on DCs(treated or immature)/MFIM on DCs(mock)) ⫻100,
where DCs are immature or treated with the cmvIL-10, LAcmvIL-10, or mock preparation. Significant differences from the mock-treated control
were determined using a one-tailed, paired Student’s t test and are indicated as follows: **, P ⬍ 0.005; ***, P ⬍ 0.0005; ****, P ⬍ 0.00005.

with determination of the site of accumulation of MHC-II
molecules in the small proportion of cells displaying a punctate
staining pattern, will therefore be important components of
future studies to compare and contrast the mechanisms of
action of these viral IL-10 proteins. Analysis of transcription
of components of the MHC-II biosynthesis pathway revealed
that MHC-II ␣ chain, ␤ chain, and invariant chain and the

master regulator of MHC-II, CIITA, were inhibited by both
LAcmvIL-10 and cmvIL-10. Thus, in addition to any potential
posttranslational interference, these data provide evidence
that both viral IL-10s act as inhibitors of CIITA, with the
consequence of decreased transcription of MHC-II components and reduced MHC-II protein expression.
While LAcmvIL-10 and cmvIL-10 both functioned to down-
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FIG. 9. Impact of LAcmvIL-10 and cmvIL-10 on proinflammatory cytokine production by MDDCs following LPS stimulation. Multiplex
ELISA-based analysis of the levels of cytokines production by DCs treated for 3 days with LPS in the presence of either purified cmvIL-10 protein
or conditioned medium (CM) from HEK293 cells transfected with either cmvIL-10 or LAcmvIL-10 expression vectors. Uninduced DCs (i.e.,
immature DCs) and LPS-induced DCs treated with mock-conditioned medium are also included. The levels of IL-1␣, IL-1␤, IL-6, TNF-␣, and
GM-CSF in the supernatants of DCs relative to LPS-induced DCs treated with mock-conditioned medium are shown, with significant differences
determined using a one-tailed, paired Student’s t test and indicated as follows: *, P ⬍ 0.05; **, P ⬍ 0.005; ***, P ⬍ 0.0005; *****, P ⬍ 0.000005;
******, P ⬍ 0.0000005; *******, P ⬍ 0.00000005.

regulate MHC-II on GM-Ps and monocytes, there were profound differences in the ability of these two viral IL-10 homologs to interfere with the maturation of DCs. Maturation of
DCs leads to phenotypic changes including upregulation of the
costimulatory and adhesion molecules CD40, CD80, CD83,
and CD86, which are involved in T-lymphocyte activation, and
increased MHC-I and -II expression on the surface of maturing
DCs (3, 43, 62). A number of studies have demonstrated that
productive HCMV infection interferes with the maturation of
DCs and their antigen-presenting function by inhibiting the
expression of these immune molecules (4, 18, 30, 38, 51).
Furthermore, Chang et al. (9) and Raftery et al. (46) showed
that stimulation of immature DCs to mature in the presence of
cmvIL-10 results in the functional paralysis of DCs (9, 46). In
our study, DCs treated with cmvIL-10 exhibited impaired LPSinduced upregulation of the DC costimulatory molecules
CD40, CD80, and CD86 and the maturation marker CD83.
cmvIL-10 was also shown to significantly inhibit the upregula-

tion of MHC-I expression on the surface of DCs in response to
LPS. However, in stark contrast to cmvIL-10, LAcmvIL-10
treatment (even at high concentrations) did not inhibit upregulation of CD40, CD80, CD83, CD86, or MHC-Ion the surfaces
of DCs in response to LPS-induced maturation. Assessment of
cytokine production by DCs treated with cmvIL-10-conditioned medium showed that cmvIL-10 had the capacity to
inhibit the secretion of IL-1␣, IL-1␤, IL-6, and TNF-␣. These
data are consistent with the cytokine profiles reported following HCMV infection of monocytes/macrophages and cytotrophoblasts (16, 17, 40, 54, 66). Importantly, treatment of LPSinduced DCs with LAcmvIL-10-conditioned medium did not
result in the alteration of cytokine production compared to
mock controls. Thus, LAcmvIL-10 and cmvIL-10 differ in their
ability to alter DC maturation, but both are able to downregulate constitutive expression of MHC-II in GM-Ps and monocytes. Despite the impact of cmvIL-10 and LAcmvIL-10 on
MHC-II expression on myeloid lineage cells, neither affected
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the expression of MHC-II on Daudi human B cell lymphoblastoma cells (55), further indicating cell-type-specific immunosuppressive functions of these viral cytokines.
The inability of LAcmvIL-10 to impair LPS-induced DC
maturation in a manner similar to cmvIL-10 may be a consequence of differences in the structure of these two proteins.
Mapping of the HCMV latency-associated UL111A region
transcript encoding LAcmvIL-10 has demonstrated retention
of a second intron which is ordinarily spliced in the transcript
encoding cmvIL-10 (19). The presence of an in-frame stop
codon within intron 2 results in the translation of the LAcmvIL10 protein that is truncated at the C terminus in comparison
to cmvIL-10. This truncation is predicted to have structural
implications on LAcmvIL-10 that may affect binding to and
signaling through the IL-10R complex. Investigations into the
functions of cmvIL-10 have also assessed the binding and signaling of the hIL-10 homolog through both IL-10R1 and IL10R2 (29, 54). Jones et al. (22) resolved the crystal structure of
the cmvIL-10 bound to soluble IL-10R1 (sIL-10R1), demonstrating that cmvIL-10 bound to two sIL-10R1 molecules as a
disulfide-linked homodimer of two interpenetrating polypeptide chains (22). cmvIL-10 and hIL-10 share similar topologies
and sIL-10R1 binding sites even though the interdomain angle
of cmvIL-10 is ⬃40o larger than that of hIL-10. Computer
predictions supported by epitope and peptide mapping data
(47, 64, 67, 68) suggest that the regions of hIL-10 likely to be
involved in contact with IL-10R1 include the N terminus, helix
A, the AB loop, part of helix B, and the C-terminal helices E/F.
Jones et al. (22) demonstrated that cmvIL-10 uses essentially
the same structural epitope as described for hIL-10 with helix
A, the AB loop, and helix F contacting sIL-10R1 (22). Studies
by Gesser et al. (15) assessed the function(s) of the C-terminal
portion of hIL-10 using a nonapeptide with homology to residues 152 to 160 (15). This peptide was found to mimic some
of the activities of intact hIL-10 such as inhibition of IL-1␤induced and spontaneous IL-8 production, downregulation of
TNF-␣ production, and inhibition of MHC-II expression on
gamma interferon-stimulated monocytes.
In the case of LAcmvIL-10, the absence of amino acid residues coded by exon 3 of the UL111A transcript results in the
loss of the C-terminal helices E/F present in cmvIL-10 (19).
This truncation may therefore result in a diminished capacity
of LAcmvIL-10 to dimerize or signal through the IL-10R complex. Indeed, we found that in contrast to treatment of monocytes with cmvIL-10 or hIL-10, LAcmvIL-10 did not induce the
phosphorylation of Stat3, a signaling molecule which is rapidly
phosphorylated upon activation of hIL-10R (14). In addition,
neutralizing antibodies to hIL-10R blocked the ability of
cmvIL-10, but not LAcmvIL-10, to downregulate MHC-II,
providing evidence of a mechanistic basis for the differences
between these proteins. LAcmvIL-10 does retain an immunomodulatory capacity as it downregulates constitutive MHC-II
expression on GM-Ps and monocytes. Thus, LAcmvIL-10 either
functions through a different, as yet unidentified receptor, or
it is still able to exert a function through the IL-10R complex
in a manner which differs from that utilized by hIL-10 and
cmvIL-10. The hIL-10 dimer is thought to have evolved from a
monomeric protein by a mechanism known as protein oligomerization or three-dimensional domain swapping. This
process may have lead to the exchange of ␣-helices E and F
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with another monomer to create the dimer with intertwining
␣-helical domains (6). A monomeric form of hIL-10 engineered by Josephson et al. (23) was able to bind to the IL-10R1
with a 1:1 stoichiometry and retained biological activity, although with reduced affinity (60-fold) and specific activity (10fold) compared to wild-type hIL-10 (23). In addition, Gesser et
al. (15) also assessed the function(s) of the N-terminal portion
of hIL-10 by generating a nonapeptide correlating to residues
8 to 16 of hIL-10 (15). While this peptide did not exhibit any
cytokine synthesis-inhibitory properties, it did downregulate
MHC-II expression. It therefore remains possible that LAcmvIL10 has the ability to bind to and signal in some way through the
IL-10R complex. Consequently, an extension of the work presented here will be to further examine LAcmvIL-10–hIL-10R
interactions to better define the mechanism of action of this
protein in the context of the hIL-10 receptor-mediated signaling
pathway and also to examine the ability of LAcmvIL-10 to form
homodimers or heterodimers with hIL-10 or cmvIL-10.
Many of the latency-associated gene products expressed by
herpesviruses have also been reported to be expressed during
the productive phase of infection. These include latency-associated transcripts (LAT) expressed by herpes simplex virus
type 1; EBNA-1, the LAT of Epstein-Barr virus; the latently
expressed varicella-zoster virus genes ORF21, ORF29,
ORF62, ORF63 and ORF4; the pseudorabies virus LAT gene;
and HCMV major immediate-early region sense LATs (CLTs)
(10, 11, 13, 21, 25, 33, 35, 39, 50, 56, 57). We have detected
RNA with features of LAcmvIL-10 transcription in RNA extracted from productively infected HFFs (20), and Chang et al.
(9) detected a protein product by Western blotting consistent
with LAcmvIL-10 when extracts from productively infected
MRC-5 cells were reacted with anti-cmvIL-10 antibody (9).
The relative contributions of cmvIL-10 and LAcmvIL-10 expression during productive infection await a more detailed
analysis of the expression from the UL111A region during this
phase of infection. In the context of latent infection, a UL111A
deletion mutant virus unable to express LAcmvIL-10 or
cmvIL-10 (42) established and reactivated from latency in experimentally infected, cultured GM-Ps in a manner comparable to its parent virus (data not shown). Together with our
identification of an immunomodulatory function, this suggests
that LAcmvIL-10 is not required directly for latent infection of
myeloid progenitors but, rather functions as an immunosuppressor to limit the immune response to latently infected cells.
To conclude, the data presented here demonstrate that a
homolog of hIL-10 expressed by HCMV during the latent
phase of infection shares some, but not all, of the immunomodulatory functions of the productive infection-associated
protein cmvIL-10. While cmvIL-10 was very effective at inhibiting the LPS activation of DCs by preventing the upregulation
of costimulatory and adhesion molecules critical to antigen
presentation, LAcmvIL-10 treatment neither hindered the upregulation of DC maturation markers nor inhibited the secretion of proinflammatory cytokines. Most significant, however,
is the finding that LAcmvIL-10 was able to downregulate constitutive MHC-II expression on the surfaces of primary human
CD14⫹ GM-Ps and monocytes. As GM-Ps and monocytes
represent a latent reservoir of HCMV, modulation of MHC-II
expression by LAcmvIL-10 during the latent phase of infection
represents a strategy that could afford the virus escape from
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immunosurveillance and increase the chances for lifelong survival.
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